VOICE: Clonidine Mucoadhesive Buccal Tablet for Chemoradiotherapy-Induced Oral Mucositis
Condition: Oropharyngeal Cancer
Sponsor: Monopar Therapeutics Inc.
Full Title
Protocol MNPR-301-001: A Phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer
Eligibility
Eligible patients will have a squamous cell carcinoma of the oropharynx without distant metastasis and will be planning to receive chemotherapy given concomitantly with radiation therapy.
Excluded are: tumors of the lips, oral cavity, sinuses, larynx, hypopharynx, nasopharynx, or salivary glands
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
